NeuroSense Therapeutics (NASDAQ:NRSN) Research Coverage Started at HC Wainwright

HC Wainwright assumed coverage on shares of NeuroSense Therapeutics (NASDAQ:NRSN) in a research report released on Thursday, MarketBeat Ratings reports. The firm issued a buy rating on the stock.

Separately, Weiss Ratings cut shares of NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $8.50.

NeuroSense Therapeutics Price Performance

Shares of NASDAQ NRSN opened at $0.51 on Thursday. The firm has a market capitalization of $19.29 million, a PE ratio of -0.95 and a beta of 1.60. NeuroSense Therapeutics has a 1-year low of $0.25 and a 1-year high of $1.98. The business’s fifty day moving average price is $0.55 and its two-hundred day moving average price is $0.71.

Insider Transactions at NeuroSense Therapeutics

In other news, CEO Alon Ben-Noon bought 250,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The shares were purchased at an average price of $0.80 per share, with a total value of $200,000.00. Following the completion of the acquisition, the chief executive officer directly owned 4,534,233 shares in the company, valued at approximately $3,627,386.40. This trade represents a 5.84% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Or Eisenberg bought 250,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The shares were purchased at an average cost of $0.80 per share, for a total transaction of $200,000.00. Following the acquisition, the chief financial officer owned 1,504,050 shares of the company’s stock, valued at $1,203,240. This represents a 19.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 27.40% of the stock is currently owned by insiders.

Institutional Trading of NeuroSense Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Squarepoint Ops LLC boosted its position in shares of NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after purchasing an additional 45,450 shares in the last quarter. Jane Street Group LLC acquired a new stake in NeuroSense Therapeutics during the second quarter valued at approximately $54,000. Two Sigma Investments LP bought a new stake in NeuroSense Therapeutics during the third quarter worth approximately $26,000. Finally, Yorkville Advisors Global LP acquired a new position in NeuroSense Therapeutics in the second quarter worth approximately $56,160. Institutional investors own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.